feed,title,long_url,short_url
Benzinga,"REV Group Q1 Results Beat Estimates, Reaffirms FY22 Guidance",https://benzinga.com/news/earnings/22/03/26064912/rev-group-q1-results-beat-estimates-reaffirms-fy22-guidance,https://bit.ly/3IXLu65
Benzinga,Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks,https://benzinga.com/analyst-ratings/analyst-color/22/03/26064811/wednesdays-with-wedbush-3-smid-cap-biotech-stock-picks,https://bit.ly/3MN3EtQ
